Basilea Pharmaceutica Ltd is continuing plans to bring its antibiotic ceftobiprole to the US market, while tightening control over its early-stage portfolio. In a report on the first-half year on 15 August, it disclosed plans to drop a preclinical, inhaled antibiotic candidate after a data review.
